What We're Reading: Page 2
Industry reads hand-picked by our editors
Dec 04, 2025
-
The Wall Street Journal
Turmoil at the FDA Threatens Biotech Recovery
-
Nature
Experimental vaccine prevents deadly allergic reactions in mice
-
Bloomberg
Lawmakers Invited to FDA Meeting for Patrick Soon-Shiong’s Drug
Dec 03, 2025
Dec 02, 2025
Dec 01, 2025
-
The Washington Post
Blaming some child deaths on covid shots, FDA vows stricter vaccine rules
-
MIT Technology Review
What we still don’t know about weight-loss drugs
-
Nature
China wants to lead the world on AI regulation — will the plan work?
Nov 26, 2025
-
Fierce Pharma
French authorities raid Sanofi headquarters in tax fraud probe
-
Science
NIH shake-up to grant decision-making draws concerns of political meddling
-
Bloomberg
Hedge Funds Pile Into Health Stocks Leading Market in Rotation
-
Medical Marketing and Media
Inside Eli Lilly’s Alzheimer’s campaign blitz during holiday season
Nov 25, 2025
-
The Washington Post
Why screening for the deadliest cancer in the U.S. misses most cases
-
Bloomberg
Where GLP-1s Weight-Loss Drugs Fall Short for Women
-
Quanta Magazine
A Cell So Minimal That It Challenges Definitions of Life
-
Stat
Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results
Nov 24, 2025
-
The Atlantic
Why Is Robert F. Kennedy Jr. So Convinced He’s Right?
-
The Economist
Chinese pharma is on the cusp of going global
-
MIT Technology Review
What’s next for AlphaFold: A conversation with a Google DeepMind Nobel laureate
-
Scientific American
What Blind Cave Fish and Venomous Snails Can Teach Us about Diabetes
Previous
